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are not expressed in cancer cells. Villa
et al. show that the RBR E3 ligase ARIH1
is expressed in several cancer cell types.
ARIH1 controls PINK1-dependent
mitophagy and sensitivity to
chemotherapies.
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Mitophagy is an evolutionarily conserved process
that selectively targets impaired mitochondria for
degradation. Defects in mitophagy are often associ-
ated with diverse pathologies, including cancer.
Because the main known regulators of mitophagy
are frequently inactivated in cancer cells, the mecha-
nisms that regulate mitophagy in cancer cells are not
fully understood. Here, we identified an E3 ubiquitin
ligase (ARIH1/HHARI) that triggersmitophagy in can-
cer cells in a PINK1-dependent manner. We found
that ARIH1/HHARI polyubiquitinates damaged mito-
chondria, leading to their removal via autophagy.
Importantly, ARIH1 is widely expressed in cancer
cells, notably in breast and lung adenocarcinomas;
ARIH1 expression protects against chemotherapy-
induced death. These data challenge the view that
the main regulators of mitophagy are tumor suppres-
sors, arguing instead that ARIH1-mediated mitoph-
agy promotes therapeutic resistance.INTRODUCTION
Mitochondria are essential for energy production, reactive
oxygen species (ROS) production, calcium buffering, and regu-
lation of several forms of cell death (Villa and Ricci, 2016;
Wallace, 2005). Over time, or in response to various stresses,
mitochondria will accumulate damage. Therefore, cells have
adopted several quality-control processes, including cycles of
mitochondrial fusion and fission and the selective elimination
of dysfunctional mitochondria by mitophagy, an organelle-spe-
cific type of macroautophagy, to maintain a functional network
of healthy mitochondria (Wei et al., 2015).
The ubiquitin (Ub) E3 ligase Parkin, which is mutated in reces-
sive familial forms of Parkinson’s disease, is a key mediator of
mitochondrial quality control processes (Kitada et al., 1998; Shi-
mura et al., 2000). Phosphatase and tensin homolog deleted on
chromosome 10-induced kinase 1 (PINK1) is a serine/threonine
kinase that shuttles between the cytosol and mitochondria in
healthy cells. Normally, it is rapidly degraded by mitochondrial
proteases, but PINK1 can stabilize on the outer membrane of2846 Cell Reports 20, 2846–2859, September 19, 2017 ª 2017 The A
This is an open access article under the CC BY-NC-ND license (http://depolarized mitochondria and recruit Parkin, which is initially
inactive (Clark et al., 2006; Narendra et al., 2008; Park et al.,
2006). PINK1 will phosphorylate Parkin on the Ub-like (UBL)
domain on the Ser65 in a DJm-dependent process, resulting in
an increase of its Ub ligase activity and the formation of polyubi-
quitin chains on the surface of depolarized mitochondrial mem-
branes. PINK1 will also phosphorylate the conserved Ser65 site
of Ub molecule (Kane et al., 2014; Kazlauskaite et al., 2015;
Koyano et al., 2014; Wauer et al., 2015). It has been proposed
that the phosphorylated Ub could act as a Parkin activator by
overcoming the autoinhibitory mechanism of Parkin. Both events
are needed to fully activate Parkin, which will, in turn, polyubiqui-
tinate numerous mitochondrial outer membrane proteins, lead-
ing to the recruitment of the Ub- and LC3-binding adaptor p62
to these damaged organelles (Herhaus and Dikic, 2015). While
p62 was initially shown to be critical for removing depolarized
mitochondria by transporting them to autophagosomes, later
studies suggested a possible redundancy with the related
Ub- and Atg8/LC3II-binding protein NBR1 (Narendra et al.,
2010; Okatsu et al., 2010), NDP52 (nuclear domain 10 protein
52, also known as CALCOCO2), or optineurin (Lazarou et al.,
2015). In particular, NDP52 and optineurin recognize phospho-
Ub, leading to the recruitment of the autophagy machinery to
initiate mitophagy (Lazarou et al., 2015).
Loss of either PINK1 or Parkin leads to accumulation of
damaged mitochondria in several models (fly, mouse, and hu-
man), further supporting their central and conserved role in mito-
chondrial quality-control pathways (Herhaus and Dikic, 2015).
A growing body of evidence has shown the involvement of
somatic Parkin inactivation in a broad panel of human cancers.
Indeed, Parkin has been shown to be downregulated in multiple
cancer cell lines and primary tumors (Gong et al., 2014; Veeriah
et al., 2010a, 2010b). Parkin-deficient mice show increased
susceptibility to tumorigenesis, while ectopic Parkin expression
reduces the in vitro or in vivo growth of cancer cells of various
origins, strongly suggesting a tumor-suppressive role for Parkin
(for review, see Xu et al., 2014). Therefore, as Parkin is often
downregulated in tumors, the molecular events that promote
mitophagy in these cells remain to be determined.
Ub and Ub-like modifications occur in a three-step enzymatic
process. E1 is an activating enzyme that forms a thioester bond
with the Ub protein. Then, the charged Ub monomer is trans-
ferred to an E2 enzyme that conjugates the Ub molecule to its
target protein, with the help of an E3 Ub ligase (Kerscheruthors.
creativecommons.org/licenses/by-nc-nd/4.0/).
et al., 2006; Nagy and Dikic, 2010). While there are few E1 and
E2 ligases, there are many diverse E3 Ub ligases that control
substrate specificity and are responsible for the enormous
diversity of the Ub system. Several different classes of E3 Ub
ligases have been identified. The RING ubiquitinases function
as a scaffold between the E2 ligase and the substrate, allowing
the transfer of the Ub moiety to the target protein. In contrast,
homologous to the E6-AP carboxyl terminus (HECT) ubiquiti-
nases play a direct role in substrate ubiquitination by forming
a catalytic intermediate thioester between the C-lobe cysteine
residue and the C terminus of Ub (Spratt et al., 2014). Recently,
E3 ligases from the Parkin family were classified as hybrids
between RING and HECT and were therefore referred to as
RING-between-RING (RBR) E3 ligases (Wenzel et al., 2011).
They are composed of a canonical RING domain, an in-be-
tween ring fingers (IBR) domain, and a RING2 domain. This fam-
ily has 14 members, including Parkin and Ariadne RBR E3 Ub
protein ligase 1 (ARIH1), also known as HHARI. For these
ligases, the first RING domain of the RBR module does not
directly transfer an E2-bound Ub onto a substrate but instead
transfers it to a Cys residue in the RING2 domain (Kulathu
and Komander, 2012).
Here, we explored the mechanism controlling mitophagy in
cancer cells. As Parkin is not expressed in most cancer cells,
we investigated how mitophagy could occur in these cells.
RESULTS
ARIH1 Expression Promotes Elimination of Depolarized
Mitochondria
Parkin is a member of the RBR family of E3 ligases that is
composed of 14 complex multidomain enzymes. As it is
frequently downregulated in cancer cells, we investigated
whether other E3 ligases could control mitophagy in these cells.
We hypothesized that another member of the RBR family could
possibly fulfill this function. A survey of the different family mem-
bers led us to focus on ARIH1, as it shares the same E2 ligase as
Parkin (UbcH7, also known asUBE2L3) (Wenzel et al., 2011), and
because an elegant study using a small interfering RNA (siRNA)-
based screen recently determined that this E3 ligase is involved
in the protection of cancer cells against genotoxic stress (von
Stechow et al., 2015).
Depolarization of the mitochondria in HeLa cells using the
protonophore carbonyl cyanide m-chlorophenyl hydrazone
(CCCP) promoted mitophagy of damaged mitochondria only
upon expression of Parkin (Figure 1A). Importantly, removal
of damaged mitochondria was also observed following
ARIH1 overexpression (Figure 1A). Indeed, after 6 hr of
CCCP treatment, we observed mitochondrial network
collapse around the perinuclear region in HeLa cells express-
ing ARIH1, as determined by TOM20 staining (Figure S1A),
while after 24 hr of CCCP treatment, we observed a complete
loss of the mitochondrial marker TOM20 (Figures 1A–1C) and
a strong reduction in COX IV, succinate dehydrogenase
iron-sulfur subunit (SDHB), and NDUFB8 expression,
mitochondrial proteins that are typically degraded during
mitophagy (Figures 1D and 1E). We observed that ARIH1-
dependent mitophagy occurred to the same extent asParkin-dependent mitophagy (Figures 1D and 1E). Impor-
tantly, as described for Parkin, ARIH1 was recruited to mito-
chondria upon CCCP treatment (Figure S1A). Thus, we
concluded that ARIH1 overexpression led to the removal of
depolarized mitochondria.
ARIH1-Mediated Removal of Damaged Mitochondria
Occurs via Mitophagy
We addressed whether the ARIH1-mediated removal of
damaged mitochondria involved mitophagy. To establish this
point, we measured mitophagy using m-Keima fluorophore, a
biosensor of mitochondrial degradation by the lysosomes
(Katayama et al., 2011). m-Keima is a variant of RFP that is tar-
geted to the mitochondrial matrix. This cellular biomarker
changes its fluorescence profile in response to pH and is resis-
tant to degradation within lysosomes. As presented in Figures
2A and 2B, we measured m-Keima conversion from green
(488 nm) to red (561 nm) fluorescence during treatment with
several mitochondria-damaging agents, such as CCCP, oligo-
mycin/antimycin (O/A), and valinomycin, using fluorescence-
activated cell sorting (FACS) (Lazarou et al., 2015). We observed
that ARIH1 could mediate mitophagy upon mitochondrial
damage to the same extent as Parkin overexpression. ARIH1-
mediated mitophagy upon mitochondrial damage was
confirmed by the strong reduction of several mitochondrial
markers, such as SDHB and NDUFB8, at the protein level (Fig-
ure 2C). Interestingly, we observed that basal mitophagy that
removes damaged mitochondria produced over time was also
dependent on ARIH1 expression (Figures S1B and S1C).
To further characterize ARIH1-dependent mitophagy induc-
tion, wemeasured autophagic flux in ARIH1- and Parkin-overex-
pressing HeLa cells following CCCP treatment. We observed an
increase of the autophagic flux as determined by the increased
conversion of LC3B-I to LC3B-II and increased degradation of
the autophagy receptor SQSTM1/p62 and the mitochondrial
protein COX IV (Figures S2B and S2C) in the presence of
ARIH1 or Parkin overexpression. Importantly, treatment with
the lysosomal inhibitor bafilomycin A1 (BafA1) further increased
LC3B-II accumulation and reduced p62 and COX IV degrada-
tion, indicating a complete autophagic response (Figures S2B
and S2C). We verified that CCCP had no effect on the expression
of those proteins in the absence of ARIH1 or Parkin expression
(Figure S2A). We also observed that LC3, ARIH1 (or Parkin
used as a positive control), and the mitochondrial marker cyto-
chrome c were co-localized on mitochondria upon CCCP treat-
ment (Figures S2D and S2E), suggesting that ARIH1 mediates
mitophagy upon mitochondrial damage. To strengthen this
point, we observed that in HeLa cells transfected with an empty
vector, LC3 was not co-localized on mitochondria upon CCCP
treatment (Figure S2F), confirming that HeLa cells cannot
perform mitophagy to a significant extent in the absence of
one of those E3 ligases.
To further investigate the role macroautophagy in ARIH1-
dependent mitophagy, we used ATG7 knockout (KO) mouse
embryonic fibroblasts (MEFs) and KO MEFs reconstituted with
ATG7-GFP (R-ATG7 MEFs; Figures 2D, 2E, and S3) (Taherbhoy
et al., 2011). Importantly, MEFs (KO and reconstituted)
expressed equivalent endogenous levels of ARIH1 but did notCell Reports 20, 2846–2859, September 19, 2017 2847
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Figure 1. ARIH1 Promotes the Removal of Damaged Mitochondria
HeLa cells were transfected to transiently overexpress the control vector (pcDNA3), ARIH1, or Parkin and then treated with the mitochondrial uncoupling agent
CCCP (10 mM) for 24 hr.
(A–C) Mitochondria were immunostained for TOM20 (green), and the absence of the mitochondrial marker TOM20 was assessed in ARIH1+ cells (B) or in Parkin+
cells (C) using confocal microscopy (scale bar, 10 mm). Quantification of mitophagywas estimated by counting aminimumof 100 cells for each condition. Data are
shown as the mean of 3 independent experiments.
(D) Whole-cell lysates were analyzed for indicated protein expression by immunoblotting (actin was used as a loading control).
(E) Data are shown as the mean ± SEM of 3 independent experiments.
***p < 0.001 and ****p < 0.0001 according to a two-way ANOVA.express Parkin (Figures 2D and S3). We observed that endoge-
nous expression of ARIH1 in MEFs was sufficient to decrease
SDHB expression (Figures 2D and 2E) following CCCP treat-
ment in reconstituted MEFs. However, this effect was not
observed in ATG7 KO MEFs. We also verified that knockdown
of endogenous ARIH1 expression using siRNA prevented
ARIH1-dependent mitophagy upon CCCP treatment in
R-ATG7 MEFs.
Collectively, these data demonstrate that ARIH1 mediates the
removal of depolarized mitochondria through mitophagy.2848 Cell Reports 20, 2846–2859, September 19, 2017ARIH1-Mediated Mitophagy Is Dependent on Its Ub
Ligase Activity and PINK1 Stabilization
To further investigate the molecular mechanisms underlying
ARIH1-mediated autophagy, we evaluated the contribution of
PINK1. To accomplish this, we first knocked down PINK1
expression using siRNAs in ARIH1-overexpressing HeLa cells.
As shown in Figures 3A and 3B, silencing of PINK1 prevented
the COX IV decrease following CCCP treatment in HeLa cells
overexpressing ARIH1. The involvement of PINK1 was further
tested by knocking out PINK1 using CRISPR/Cas9 (Figures 3C
AB
D E
C
Figure 2. ARIH1 Removes Damaged Mitochondria via Autophagy
(A) HeLa cells overexpressing pcDNA3, ARIH1, or Parkin were transfected with m-Keima; treated with CCCP (10 mM), oligomycin/antimycin A (O/A; 25 nM and
250 nM, respectively), or valinomycin (10 nM) for 24 hr; and analyzed by flow cytometry. Green fluorescence of m-Keima reflects mitochondria in the cytosol
(FLmito, green), while red fluorescence reflects mitochondria in lysosomes (FLlyso, red). The ratio of mitophagy is reflected by the percentage of cells in the top
panel.
(B) Data are shown as the mean ± SEM of 3 independent experiments performed as in (A).
(legend continued on next page)
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and 3E) in HeLa cells overexpressing ARIH1. Indeed, while
ARIH1 decreased COX IV (Figures 3C and 3D) and increased
conversion from green to red m-Keima following CCCP treat-
ment (Figure 3E), both effects were blunted upon PINK1 KO.
Equivalent results were obtained upon treatment with othermito-
chondria-damaging agents (Figure 3E).
It has been shown that during mitophagy, PINK1 phosphory-
lates Parkin and Ub on Ser65. We established here that in
response to CCCP treatment, ARIH1 was phosphorylated on a
Ser/Thr residue (Figure 3F), suggesting that phosphorylation by
PINK1 is the first step in ARIH1-mediated mitophagy. Thus,
ARIH1-dependent mitophagy requires PINK1 expression.
We then verified that the mitochondria of ARIH1-expressing
HeLa cells were polyubiquitinated upon CCCP treatment as
determined by the increase in Ub staining that co-localized
with TOM20 staining on the mitochondria (Figure 4A). We also
established that upon relocalization to the mitochondria, ARIH1
expression leads to TOM20 and MFN2 (mitofusin 2) degradation
in a proteasomal-dependent manner, as MG132 could prevent it
(Figure 4B).
We then used a mutant of ARIH1 with deletions in the RING
type 1, IBR type, and RING type 2 domain (referred to as
DARIH1). As previously shown, overexpression of full-length
ARIH1 or Parkin resulted in mitophagy upon CCCP treatment,
as determined by the conversion of m-Keima from green to
red (Figure 4C) and the decrease in COX IV and SDHB expres-
sion (Figures 4D and 4E). In contrast, while DARIH1 was
overexpressed to the same extent as full-length ARIH1, it
did not lead to mitophagy (Figures 4C–4E) upon CCCP
treatment.
We could therefore conclude that ARIH1 induces mitophagy
by polyubiquitination of the damaged mitochondria, leading to
its removal by the autophagic machinery.
ARIH1 Is Overexpressed in Cancer Cells and Is the Main
Regulator of Mitophagy in These Cells
After establishing ARIH1 as a regulator of mitophagy, we as-
sessed its expression in various cell lines and tissues (Figures
5A, 5B, and S4). ARIH1 mRNA was widely expressed in human
cancer tissues and cancer cell lines, with strong expression in
lung adenocarcinoma samples (Figures S4A and S4B). We
then investigated ARIH1 protein expression in a panel of
9 different human cancer cell lines (Figure 5A). In contrast to
Parkin, which was not expressed in any of the tumor cell lines
tested (either at the protein or mRNA level; Figures 5A, 5B, and
S4C), ARIH1 was endogenously expressed in several of them
(Figures 5A and 5B), with the highest expression in lung cancer
cell lines (A549 and H1975).
We then determined whether endogenous expression of
ARIH1 could activate mitophagy upon mitochondrial depolariza-
tion. To accomplish this, A549 and H1975 cells were incubated(C) Whole-cell lysates were treated as in (A) and analyzed for SDHB, NDUFB8, P
loading control).
(D) Mitophagy was analyzed in MEF KO ATG7 cells and MEF KO cells reconstit
siRNA targeting ARIH1 by immunoblotting for SDHB or PINK1.
(E) Data are shown as the mean ± SEM of 3 independent experiments.
***p < 0.001, ****p < 0.0001 according to a two-way ANOVA.
2850 Cell Reports 20, 2846–2859, September 19, 2017with increasing amounts of a decoupling agent, and mitophagy
was assessed by measuring COX IV expression. As shown in
Figures 5C and 5D, COX IV expression was reduced upon
decoupling of the mitochondria. This removal of damaged mito-
chondria was associated with an increase in autophagic markers
(LC3 conversion and decrease in p62 expression; Figure 5E),
altogether indicating that endogenous ARIH1 expression in
lung cancer cell lines induced the removal of damaged mito-
chondria through mitophagy.
Importantly, we then demonstrated using three independent
siRNAs that ARIH1 knockdown was sufficient to prevent
CCCP-induced mitophagy as determined by the absence of
the decrease in COX IV expression (Figure 6A). Equivalent
results were obtained in H1975 cells following CCCP treatment
(Figure S5A). To further support our observations, we per-
formed a rescue experiment by knocking down endogenous
ARIH1 expression in A549 cells, and we re-expressed an
siRNA-resistant ARIH1-FLAG. As presented in Figures 6B, 6C,
and S5B, mitophagy was not observed upon ARIH1 knockdown
in the presence of CCCP or O/A, while ARIH1-FLAG expression
restored it. We then measured mitophagy using m-Keima (as
done previously) using a mitochondrial-damaging treatment
(O/A). Mitophagy was blunted upon ARIH1 knockdown (Fig-
ure 6C), while it was observed when ARIH1-FLAG was
expressed (Figure 6D).
We then deleted PINK1 expression using a CRISPR/Cas9
interference technique to validate the implication of this kinase
in ARIH1-mediated mitophagy upon endogenous expression of
this E3 ligase (Figures 6E and 6F). While mitochondrial network
collapse around the perinuclear region and PINK1 induction
(two early signs of mitophagy) could be observed in control cells,
these markers were absent in A549 cells lacking PINK1. Simi-
larly, COX IV reduction following CCCP treatment was not
observed in cells lacking PINK1 (Figure 6F). We confirmed that
the removal of damaged mitochondria in A549 cells was indeed
mediated through mitophagy, as a cellular invalidation of ATG12
or ATG7 using the CRISPR/Cas9 technique (Wang et al., 2014)
prevented CCCP-induced COX IV degradation and m-Keima
conversion (Figures 6G–6I).
It was recently suggested that optineurin and NDP52 are key
cargo adaptors for Parkin-mediated mitophagy (Heo et al.,
2015; Lazarou et al., 2015; Richter et al., 2016). We therefore
knocked down their expression using specific siRNA (Figures
S5C and S5D) to evaluate their implication in ARIH1-mediated
mitophagy. While respective protein expression was massively
reduced in A549 cells, it did not prevent the COX IV decrease
observed upon CCCP treatment, altogether indicating that
neither optineurin nor NDP52 acts as a cargo adaptor for
ARIH1-mediated mitophagy. MFN2 was recently suggested to
be a mitochondrial receptor for Parkin that is required for
mitophagy (Chen and Dorn, 2013). Using two independentINK1, Parkin, and ARIH1 expression by immunoblotting (actin was used as a
uted with ATG7-GFP (R-ATG7 MEFs) transfected with an siRNA control or an
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Figure 3. ARIH1-Dependent Mitophagy Requires PINK1
HeLa cells overexpressing ARIH1 were transfected with an siRNA control or an siRNA targeting PINK1 and treated with CCCP (10 mM) for the indicated times.
(A) Whole-cell lysates were analyzed for COX IV, PINK1, and ARIH1 expression by immunoblotting (ERK2 was used as a loading control).
(B) Data are shown as the mean ± SEM of 3 independent experiments.
(C–E) HeLa-expressing ARIH1 were transfected with a control construct (CRISPR CTL) or CRISPR/Cas9 construct in order to delete PINK1 and then treated with
CCCP (10 mM) for the indicated times.
(C) Whole-cell lysates were analyzed for COX IV, PINK1, and ARIH1 expression by immunoblotting (ERK2 was used as a loading control).
(D) Data are shown as the mean ± SEM of 3 independent experiments.
(E) HeLa cells CRISPR CTL or CRISPR PINK1 ARIH1 were transfected with m-Keima; treated with CCCP (10 mM), oligomycin/antimycin A (O/A; 25 nM and
250 nM, respectively), or valinomycin (10 nM) for 24 hr; and analyzed by flow cytometry as in Figures 2A and 2B. Data are shown as the mean ± SEM of 3
independent experiments.
(F) HeLa cells were transfected with pcDNA3 or FLAG-ARIH1 plasmids. Cells were left untreated (left) or treated with CCCP (10 mM) for 4 hr (right). ARIH1 was
immunoprecipitated (IP) with an anti-FLAG antibody followed by immunoblotting for phospho-Ser/Thr antibody. Actin was used as a loading control.
*p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001 according to a two-way ANOVA. N.S: non-significant.siRNAs, we established that MNF2 knockdown does not impair
ARIH1-mediated mitophagy or sensitivity to cisplatin (Figures
S5E–S5H).
Overall, we detected endogenous expression of ARIH1 in
several cancer cell lines, including lung cancer cells, and estab-
lished that ARIH1 is the main regulator of PINK1-dependent
mitophagy upon mitochondrial damage.ARIH1-Mediated Mitophagy Controls the Sensitivity of
Lung Cancer Cells to Chemotherapy-Induced Death
After we identified ARIH1 as an endogenous regulator of mitoph-
agy in lung cancer cells, we then decided to investigate its role in
cell sensitivity or resistance to chemotherapy. We first investi-
gated whether modulation of ARIH1 expression had an impact
on cell survival. To accomplish this, HeLa cells expressingCell Reports 20, 2846–2859, September 19, 2017 2851
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Figure 4. ARIH1-Dependent Mitophagy Requires Its Ub Ligase Activity
(A) ARIH1-overexpressing HeLa cells were treated with CCCP (10 mM) and co-immunostained for TOM20 (pink), Ub (green), and ARIH1 (red). Co-localization was
analyzed by confocal microscopy (scale bar, 10 mm).
(B) HeLa cells were transiently transfected with a control vector (pcDNA3), ARIH1, or Parkin and were treated with the mitochondrial uncoupling agent CCCP
(10 mM) for 24 hr alone or with MG132 (10 mM). Whole-cell lysates were analyzed for TOM20, MFN2, PINK1, ARIH1, and Parkin expression by immunoblotting
(ERK2 was used as a loading control).
(C) HeLa cells overexpressing pcDNA3, ARIH1, Parkin, or a truncated form of ARIH1 (DARIH1-FLAG) were transfected with m-Keima and treated with CCCP
(10 mM) for 24 hr and analyzed by flow cytometry as in Figures 2A and 2B. Data are shown as the mean ± SEM of 3 independent experiments.
(D and E) HeLa cells were transiently transfected with a control vector (pcDNA3), ARIH1-FLAG, Parkin, or a truncated form of ARIH1 (DARIH1-FLAG) and treated
with the mitochondrial uncoupling agent CCCP (10 mM) for 24 hr.
(D) Whole-cell lysates were analyzed for COX IV, SDHB, PINK1, ARIH1, Parkin, and FLAG expression by immunoblotting (actin was used as a loading control).
(E) Data are shown as the mean ± SEM of 3 independent experiments.
**p < 0.01 and ****p < 0.0001 according to a two-way ANOVA.ARIH1 were treated with CCCP, and wemonitored their ability to
grow as clones (clonogenic test). We observed that while only a
few control HeLa cells could grow after CCCP treatment, the
number of clones was significantly increased in cells expressing
ARIH1 (Figure 7A), suggesting a protective effect of ARIH1
following mitochondrial damage.
We then verified that ARIH1 knockdown in A549 cells did not
affect CCCP-induced mitochondrial depolarization (Figure S6A)2852 Cell Reports 20, 2846–2859, September 19, 2017or the ability of these cells to form colonies (Figure 7B). In
contrast, knockdown of endogenous ARIH1 was sufficient to
reduce the ability of A549 cells to survive following treatment
with CCCP (Figure 7B). Indeed, two independent siRNAs target-
ing ARIH1 sensitized A549 cells to CCCP-induced apoptosis, as
shown by an increase in PARP cleavage (Figure 7C), an increase
in DEVDase activity (Figure 7D), and an increase in sub-G1 DNA
content (Figure 7H), typical hallmarks of apoptosis. This
Figure 5. ARIH1 Is Overexpressed in Breast and Lung Cancer Cells
(A) Immunoblots of ARIH1 and Parkin in the indicated cancer cell lines and healthy skin sample (used as a positive control for endogenous Parkin expression).
ERK2 was used as a loading control.
(B) The ratio of ARIH1 or Parkin to ERK2 expression (average of 2 independent experiments).
(C) A549 and H1975 lung cancer cell lines were treated with CCCP (from 1 to 10 mM) for 24 hr. The decrease in mitochondrial mass was analyzed by immu-
noblotting COX IV.
(legend continued on next page)
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sensitization to CCCP-induced apoptosis following ARIH1
knockdown was also observed in H1975 cells (Figures S6B
and S6C).
The alkylating agent cisplatin is a standard treatment for
several cancers, including lung carcinomas. We therefore inves-
tigated whether endogenous ARIH1 expression could affect
cisplatin-induced cell death. We selected a dose of cisplatin
with a limited ability to prevent control A549 cell growth (trans-
fected with a scramble siRNA). Strikingly, the same treatment
substantially impaired the growth of ARIH1 knockdown A549
cells (Figure 7E) and sensitized these cells to apoptosis, as
shown by the increase in PARP cleavage (Figure 7F), DEVDase
activity (Figure 7G), and sub-G1 DNA content (Figure 7H). We
confirmed that the decrease in mitochondrial potential (DJm)
upon cisplatin treatment was not altered in ARIH1 knockdown
cells, indicating that this E3 ligase acts downstream of the mito-
chondrial dysfunction (Figure S6D).
We demonstrated that ARIH1 functions both in mitophagy and
in resistance to cisplatin. To determine whether ARIH1 promotes
resistance to chemotherapy throughmitophagy, we knocked out
the molecular actors implicated in ARIH1-mediated mitophagy
(PINK1, ATG7, and ATG12) in A549 cells. KO of those key
proteins sensitized cells to various types of chemotherapy-
induced death (Figures 7I, 7J, and S7A), suggesting that lung
cancer cells use mitophagy as a defense mechanism against
chemotherapy-induced cell death.
Finally, Parkin was recently suggested to regulate Bax levels
and promote resistance to apoptosis independently of mitoph-
agy (Cakir et al., 2017; Johnson et al., 2012). We did not observe
any regulation of Bax or Bak levels upon ARIH1 modulation or
PINK1 KO, suggesting that ARIH1-dependent control of cell
death was not mediated by the regulation of the level of expres-
sion of those Bcl-2 members (Figures S6E–S6G). These results
suggest that ARIH1-dependent mitophagy is protective in can-
cer cells.
DISCUSSION
The removal of dysfunctional mitochondria is required to main-
tain a healthy mitochondrial network and promote cell survival
in response to certain stresses. How mitophagy promotes the
turnover of damaged mitochondria that would otherwise injure
the cell has not been fully elucidated. The most extensively char-
acterized mitophagy regulators are Parkin/PINK1, BNIP3, and
NIX (known as BNIP3L), which have non-overlapping roles in
promoting autophagy (for review, see Chourasia et al., 2015).
Importantly, in most cancers, BNIP3, NIX, and Parkin expression
has been shown to be downregulated, indicating their role as
tumor suppressors. Indeed, significant deletions of the BNIP3
locus at 10q26.3 were observed in half of the human tumor
types, including lung carcinomas (Beroukhim et al., 2010). In
addition, epigenetic silencing of BNIP3 expression as tumors
progress to invasion and metastasis has been reported (Calvisi(D) Data are shown as the mean ± SEM of 3 independent experiments.
(E) A549 and H1975 lung cancer cell lines were treated with 10 mMCCCP for the in
and P62. ERK2 was used as a loading control.
**p < 0.01 according to a two-way ANOVA.
2854 Cell Reports 20, 2846–2859, September 19, 2017et al., 2007; Erkan et al., 2005). Similarly, Parkin (PARK2) maps
to a common fragile site on human chromosome 6q25-q26
that is frequently deleted in cancers (Cesari et al., 2003). There-
fore, until now themain regulators ofmitophagywere considered
as tumor suppressors and, therefore, the vast majority of the
studies suggesting that the removal of damaged mitochondria
could play a role in the survival of cancer cells following chemo-
therapeutic treatment could only be obtained after ectopic
expression of those genes.
In sharp contrast, we identify here that the E3 ligase ARIH1 is
regulator of PINK1-dependent mitophagy (Figures 1, 2, 3, and 4)
that is overexpressed in several cancers, including lung adeno-
carcinomas (Figures 5, 6, and S4). We established that ARIH1-
dependent control of mitophagy was indeed dependent on its
Ub ligase activity (Figure 4). Importantly, we showed that
ARIH1 overexpression is associated with resistance to chemo-
therapeutic-induced apoptosis (Figure 7).We also demonstrated
that removal of ARIH1 or of key mitophagy or autophagy regula-
tors sensitized tumor cells to chemotherapy-induced death (Fig-
ure 7), suggesting that mitophagy is protective in those cells,
although we cannot formally exclude at this stage that other
cellular functions of those proteins (which remain to be identified)
are partially involved in the described effect.
Our results also suggest that ARIH1, as opposed to Parkin,
BNIP3, or NIX, could be a predictive marker of chemotherapy.
This notion is supported by the observation that lung adenocar-
cinoma patients with high levels of ARIH1 showed decreased
survival after treatment (Figure S7B).
ARIH1 is a 557-amino-acid protein (64 kDa) distributed in the
cytoplasm and the nuclei of cells (Figure 1A; Elmehdawi et al.,
2013) that shares many structural and functional properties
with Parkin (Parelkar et al., 2012). It is highly conserved, sharing
72% and 98% amino acid sequence identity with the Drosophila
and mouse genes, respectively (Tan et al., 2000). Despite the
widespread distribution of ARIH1 transcripts (Moynihan et al.,
1999) and the lethality of KOs (Aguilera et al., 2000), its cellular
functions are not well characterized. It was previously reported
that ARIH1 levels were higher in cancer tissues than in normal tis-
sues of the same origin (Elmehdawi et al., 2013), as opposed to
the other known regulators of mitophagy. The same study
reported that increased ARIH1 expression was associated with
enhanced cell proliferation (Elmehdawi et al., 2013). Mechanisti-
cally, a yeast two-hybrid screen suggested an interaction be-
tween ARIH1 and the protein translation initiation factor eIF4E2
(Tan et al., 2003), suggesting a role in protein translation or
RNA processing. It was later shown that this interaction with
eIF4E2 was required for the protection of embryonic stem cells
(ESCs) from DNA damage (von Stechow et al., 2015). However,
whether this ARIH1-dependent control of mRNA translation
arrest is required for the control of mitophagy in cancer cells is
not known and will be the subject of further studies.
At the molecular level, it will be important to uncover how
PINK1 activates ARIH1. Recently, ARIH1 was shown to be adicated times, and autophagy induction was assessed by immunoblotting LC3
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Figure 6. ARIH1 Induces Mitophagy in Lung Cancer Cells
A549 cells were transfected with the indicated siRNAs and treated with increasing amounts of CCCP (from 1 to 10 mM) for 24 hr.
(A) Whole-cell lysates were analyzed for COX IV, PINK1, and ARIH1 expression by immunoblotting (ERK2 was used as a loading control).
(B and C) A549 cells were transfected with the indicated siRNAs and then transfected with either an empty vector or FLAG-ARIH1 in order to rescue the
knockdown of ARIH1 expression.
(B) Cells were treatedwith increasing amounts of CCCP (from 1 to 10 mM).Whole-cell lysates were analyzed for SDHB, NDUFB8, PINK1, and ARIH1 expression by
immunoblotting (actin was used as a loading control).
(legend continued on next page)
Cell Reports 20, 2846–2859, September 19, 2017 2855
new component of the cullin-RING E3 ligases (CRLs), which spe-
cifically mediate monoubiquitylation of several substrates (Scott
et al., 2016). We therefore speculate that this novel role of ARIH1
could at least in part be involved in PINK1-mediated mitophagy,
possibly through direct interaction with PINK1. PINK1 is a Ser/
Thr kinase stabilized at the outer membrane of depolarized mito-
chondria, and it can phosphorylate Parkin in its UBL domain in
order to overcome its autoinhibitory mechanism. Here, we
show that ARIH1, after a brief exposure to CCCP, can also be
phosphorylated on a Ser/Thr residue (Figure 3F). It is important
to note that, like Parkin, ARIH1 also has an inhibitory (Ariadne)
domain masking the RING type 2 domain containing catalytic
activity. Furthermore, this Ariadne domain contains eight serine
residues and two threonine residues that could potentially be
phosphorylated by PINK1, leading to the unmasking of the
ARIH1 catalytic site. Also, we established that ARIH1-mediated
mitophagy and protection from chemotherapy-induced death
was dependent on PINK1 expression, but not on NDP52, opti-
neurin, MFN2, Bax, or Bak expression (Figure S5), suggesting
that ARIH1 has a different set of targets than Parkin that remains
to be identified.
Another open question is how ARIH1 is overexpressed in
cancer cells. A screen of different public databases indicated
that ARIH1 mRNA expression is upregulated in a wide variety
of cancer tissues. As an example, a survey of Tumorscape
(Broad Institute, Cambridge, MA, USA) (Beroukhim et al.,
2010) indicated that ARIH1 was overexpressed in colorectal
and medulloblastoma as well as in 21 out of 40 lung squamous
carcinoma samples (tissues/cell lines) present in the database.
These data suggest that transcriptional regulation of ARIH1 may
be involved. However, the transcription factors involved have
not been identified. Therefore, in addition to gene expression,
the regulation of ARIH1 protein stability cannot be excluded at
this stage.
The role of Parkin in the regulation of cell death is debated.
While it is widely assumed to inhibit cell death, it was recently
shown that several anti-apoptotic members of the Bcl-2 family
could prevent Parkin translocation to the depolarized mitochon-
dria and therefore regulate the onset of Parkin-dependent mito-
chondrial clearance (Hollville et al., 2014). It was then suggested
that Parkin activation in response to mitochondrial dysfunction
resulted in apoptosis by promoting the degradation of Mcl-1, a
pro-survival gene of the Bcl-2 family (Carroll et al., 2014). These
results suggest a close link between Parkin and the Bcl-2 family.(C) Cells were treated with oligomycin/antimycin A (O/A; 25 nM and 250 nM, respe
and ARIH1 expression by immunoblotting (actin was used as a loading control).
(D) A549 were transfected with the indicated siRNAs and m-Keima, treated with
cytometry as in Figures 2A and 2B. Data are shown as the mean ± SEM of 3 ind
(E) A549 control cells (CRISPRCTL) and A549 cells invalidated for PINK1 (CRISPR
and co-immunostained for TOM20 (green), PINK1 (pink), and ARIH1 (red). Co-loc
(F) A549 CRISPR CTL and CRISPR PINK1 cells were treated for 24 hr with CC
expression by immunoblotting (ERK2 was used as a loading control).
(G) A549 CRISPR CTL and CRISPR ATG12 cells were treated as described in (F
(H) A549 CRISPR CTL and CRISPR ATG7 cells were treated for 24 hr with increas
COX IV, PINK1, ATG7, and ARIH1 expression by immunoblotting (ERK2 was use
(I) A549 CRISPR CTL and CRISPR ATG7 were transfected with m-Keima, treated
and 2B. Data are shown as the mean ± SEM of 3 independent experiments.
***p < 0.001 according to a two-way ANOVA.
2856 Cell Reports 20, 2846–2859, September 19, 2017However, as Parkin is rarely expressed in cancer cells, it would
be interesting to investigate whether ARIH1 can interact with
and control these pro-survival factors, as (1) ARIH1 was reported
to limit protein translation, and (2) Mcl-1 has a short half-life and
is strongly affected by a block in translation (Meynet et al., 2012,
2013; Pradelli et al., 2010).
Finally, it was recently suggested that PINK1 could induce
mitophagy directly through phospho-Ub-mediated recruitment
of autophagy receptors (Lazarou et al., 2015). While this inter-
esting observation might be relevant to cells that do not express
significant levels of Parkin or ARIH1, these results should be
interpreted with caution in cells expressing ARIH1 (such as
breast or lung cancer cell lines).
In conclusion, we show here that ARIH1 is a regulator of
mitophagy in cancer cells that is involved in the protection of
these cells from chemotherapy-induced death. This report chal-
lenges the view that the main regulators of mitophagy are tumor
suppressors and suggests that ARIH1 may facilitate the removal
of damaged mitochondria to promote tumor resistance to
chemotherapy. While the association between Parkin genotype
and cancer susceptibility is still under debate (Alcalay et al.,
2012), our work indicates that ARIH1 is a potential therapeutic
target and potentially a predictive marker of lung cancer sensi-
tivity to chemotherapy.
EXPERIMENTAL PROCEDURES
Cell Death Measurement
To induce cell death, cells were treated with CCCP, cisplatin, or etoposide or
irradiated with a UV lamp (254 nm) with the indicated doses. Cell death was
analyzed either by DEVDase activity or DAPI staining. To assess DEVDase ac-
tivity, cells were lysed in buffer (10 mM HEPES [pH 7.4], 150 mM NaCl, 5 mM
EDTA, 1%NP40, 10 mg/mL aprotinin, 1 mM PMSF, and 10 mM leupeptin) 16 hr
after treatment. Lysates were standardized for protein content and loaded into
a black 96-well plate (CellStar) in the presence of 0.2 mmol/L of the caspase-3
substrate Ac-DEVD-AMCdiluted in the following buffer: 50mmol/L HEPES (pH
7.5), 150 mmol/L NaCl, 20 mmol/L EDTA, and 10 mmol/L DTT. Caspase activ-
ity was determined both with and without the presence of 1 mmol/L Ac-DEVD-
CHO using a fluoroscan at 460 nm, and specific activity was expressed as the
change in absorbance per minute per milligram protein.
In parallel, cell viability of the treated cells was assessed by looking at the
plasma membrane permeabilization using DAPI staining and then analyzed
by flow cytometry (Miltenyi Biotec).
For the cell cycle experiments, cells treated for 16 hr were permeabilized in
70% ethanol overnight at 20C and washed with PBS. Cells were incubated
with PBS, RNase (20 mg/mL), and propidium iodide (50 mg /mL, Sigma Aldrich)
for 30 min at 4C and then analyzed by flow cytometry (Miltenyi Biotec).ctively) for 24 hr. Whole-cell lysates were analyzed for SDHB, NDUFB8, PINK1,
O/A (25 nM and 250 nM, respectively) for 24 hr, and then analyzed by flow
ependent experiments.
PINK1) by the CRISPR/Cas9 technique were treated for 6 hr with CCCP (10 mM)
alization was analyzed by confocal microscopy (scale bar, 10 mm).
CP (10 mM). Whole-cell lysates were analyzed for COXIV, PINK1, and ARIH1
).
ing amounts of CCCP (from 1 to 10 mM). Whole-cell lysates were analyzed for
d as a loading control).
with CCCP (10 mM) for 24 hr, and analyzed by flow cytometry as in Figures 2A
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Figure 7. ARIH1 Protects Lung Cancer Cells from Cell Death
(A) Clonogenic assay of HeLa control cells (pcDNA3) or cells overexpressing ARIH1, which were treated with CCCP (10 mM) for 6 hr. Pictures were taken 10 days
after treatment.
(B) Clonogenic assay of A549 control cells (siCont) or ARIH1-silenced cells (siARIH1), which were treated with CCCP (10 mM) for 6 hr. Pictures were taken 5 days
after treatment.
(C and D) A549 cells silenced for ARIH1with two different siRNAswere treatedwith increasing concentrations of CCCP (from 1 to 10 mM). Apoptosis was analyzed
by immunoblotting for PARP cleavage (C) and DEVDase activity (D).
(legend continued on next page)
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Mito Keima Mitophagy Analysis
HeLa cells and A549 cells were transfected with m-Keima and then analyzed
by flow cytometry (Miltenyi Biotec) as previously reported (Lazarou et al.,
2015). Excitation 458 nm and emission >650 nm were used to detect m-Keima
in mitochondria in the cytosol (FLmito, green). Excitation 561 nm and emission
>650 nm were used to detect mitochondria in lysosomes (FLlyso, red).
Statistical Methods
Data are expressed as mean ± SEM. Differences in the calculated means
between groups were assessed by two-way ANOVA.
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